Interpace Diagnostics Changes Name to Interpace Biosciences; Announces Plans for Next Phase of Growth and Third Quarter 2019 Financial Results
November 13, 2019 16:40 ET
|
Interpace Biosciences, Inc.
Third Quarter Revenue Grew 34% Over the Prior Year’s Quarter and 25% Year to Date Acquired BioPharma Business in Partnership with Ampersand Diagnostic Test Volume Grew 16% for the Quarter and...
Interpace to Host Conference Call and Webcast to Discuss Third Quarter 2019 Financial Results on Wednesday, November 13, 2019
November 12, 2019 06:55 ET
|
Interpace Diagnostics Group, Inc.
PARSIPPANY, NJ, Nov. 12, 2019 (GLOBE NEWSWIRE) -- Interpace (IDXG) announced today that it will report its third quarter 2019 financial results on Wednesday, November 13, 2019 at 4:30 p.m. ET....
Interpace Diagnostics Announces Publication of New Data on Thyroid Test Utility
November 04, 2019 06:55 ET
|
Interpace Diagnostics Group, Inc.
Clinical Data Highlights the Utility of ThyGeNEXT® and ThyraMIR® PARSIPPANY, NJ, Nov. 04, 2019 (GLOBE NEWSWIRE) -- Interpace Group (NASDAQ: IDXG) Interpace Diagnostics announced today the...
Interpace to Present Data at the ATA Annual Meeting
October 29, 2019 06:55 ET
|
Interpace Diagnostics Group, Inc.
PARSIPPANY, NJ, Oct. 29, 2019 (GLOBE NEWSWIRE) -- Interpace (IDXG) announced today that it will be presenting new data on the performance of its molecular thyroid products at the upcoming 89th...
Interpace to Present at the American College of Gastroenterology Conference
October 24, 2019 06:55 ET
|
Interpace Diagnostics Group, Inc.
Interpace hosts 2nd Annual Fellow Programs PARSIPPANY, NJ, Oct. 24, 2019 (GLOBE NEWSWIRE) -- Interpace (IDXG) announced today that it will be presenting new data on the performance of its...
Interpace Announces Closing of $13 Million Second Tranche Acquisition Financing from Ampersand Capital Partners
October 17, 2019 06:55 ET
|
Interpace Diagnostics Group, Inc.
PARSIPPANY, NJ, Oct. 17, 2019 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (IDXG) announced today that it has closed on a $13 million Convertible Preferred Stock investment by Ampersand...
Interpace Named to ‘Most Admired Companies’ List
October 15, 2019 06:55 ET
|
Interpace Diagnostics Group, Inc.
PARSIPPANY, NJ, Oct. 15, 2019 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (NASDAQ: IDXG) announced today that it has been named one of the 50 Most Admired Companies of the Year by The...
Interpace Announces New Contracts with Multiple Blue Cross Blue Shield Plans
September 30, 2019 06:55 ET
|
Interpace Diagnostics Group, Inc.
In-Network Access for Thyroid Assays for More than 5 Million Members PARSIPPANY, NJ, Sept. 30, 2019 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (NASDAQ: IDXG) announced today that it...
Interpace to Present at The Ladenburg Thalmann 2019 Healthcare Conference
September 18, 2019 06:55 ET
|
Interpace Diagnostics Group, Inc.
PARSIPPANY, NJ, Sept. 18, 2019 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (“Interpace” or the “Company”) (NASDAQ: IDXG) today announced that the Company will present at the upcoming...
Interpace Enters Strategic Partnership Agreement with Genecast Biotechnology to Partner with Biopharma Solutions in China
September 16, 2019 06:55 ET
|
Interpace Diagnostics Group, Inc.
PARSIPPANY, NJ, Sept. 16, 2019 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc.’s subsidiary, Interpace BioPharma Inc. (“Interpace”, “Interpace BioPharma” or the “Company”) today announced that...